Compare Illumina, Inc. (ILMN) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Marqeta Inc — how do they compare? Illumina, Inc. trades at $192.36 (market cap $27.94B), while Marqeta Inc trades at $17.21 (market cap $1.85B). The key difference: Illumina, Inc. is far larger — about 15.1× Marqeta Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals.
| ILMN | MQ | |
|---|---|---|
Market Cap | $27.94B | $1.85B |
Sector | Health | Technology |
52-Week High | $194.33 | $27.32 |
52-Week Low | $91.00 | $15.04 |
Enterprise Value | $29.33B | $1.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $192.53, up 3.15% today, with bullish technical signals and strong fundamental recovery. The stock shows robust profitability with a 19.42% net margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and new executive appointments, reinforcing growth prospects in genomics.
Outlook remains positive driven by sequencing demand and cost control, but risks include competitive pressure from Roche's new sequencer and China market weakness. Analyst consensus is Buy with a $178 target, though the current price exceeds this, suggesting cautious optimism amid execution risks.
MQ trades at $17.44, down slightly by 0.29% today. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Recent financials reveal revenue growth to $624.88M in 2025, but profitability remains weak with a net margin of -2.23%. The company's expansion into Europe with Expensify and a recent 4:1 reverse stock split are key developments. Analyst consensus is a 'Buy' with a $19.00 price target, indicating modest upside potential.
MQ presents a cautious opportunity with growth initiatives offset by profitability challenges. The stock's high P/E of 439 reflects investor optimism on future earnings, but thin margins and inconsistent quarterly results pose risks. Upside depends on successful execution of European expansion and sustained revenue growth, while downside risks include competitive pressures and failure to achieve profitability. Institutional sentiment is mixed, with 59% of analysts recommending 'Hold'.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
